Recently, Pri Pharmaceuticals received a marketing license for injectable ganciclovir issued by the Guatemalan National Drug Administration, which indicates that the injectable ganciclovir produced by Pri Pharmaceuticals is eligible to be marketed and sold in Guatemala.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.